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ABSTRACT 
Cardiovascular diseases are the leading cause of death worldwide as reported by 
the World Health Organization. Biomaterials have been extensively used in blood-
contacting applications as heart valves, stents, grafts and catheters. However failure due 
to thrombosis hinders the long term patency and potential of these devices. Purified 
elastin scaffolds derived from porcine arteries as potential vascular graft materials are 
being investigated in our laboratory. In this study, we investigated the influence of factors 
such as shear stress and the presence of plasma proteins on the platelet response, and 
endothelial cell retention on purified elastin scaffolds to evaluate their 
hemocompatibility.  
Elastin scaffolds showed minimal platelet attachment and activation as compared 
to collagen scaffolds under physiologically relevant conditions – in the presence of shear 
and plasma proteins. Also, the absence of plasma proteins significantly augmented the 
platelet response to the underlying substrate, especially under shear. Contribution of 
fibrinogen adsorption towards platelet attachment was studied by Circular Dichroism. 
Although a higher amount of fibrinogen was adsorbed on elastin surfaces than collagen, 
the conformation of adsorbed protein was similar to native fibrinogen on both collagen 
and elastin surfaces. Therefore, with our testing conditions, the role of fibrinogen in 
contributing to the difference in platelet activity on these two scaffolds was not apparent. 
Plasma recalcification time reasserted thromboresistance of elastin scaffolds showing 
more than a two fold increase in clotting time as compared to collagen.  
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The purified elastin scaffolds showed good retention of endothelial cells in static 
cultures but when cells were plated under shear significantly lower number of cells were 
able to attach to elastin surfaces. Role of integrins in endothelial cell adhesion was 
studied by adhesion inhibition assays. Both αv and β1 receptor subunits exhibited a 
significant contribution to the endothelial adhesion process to elastin scaffolds as 
blocking these receptors by their respective antibodies significantly lowered the number 
of cells attached to elastin under static conditions.  
Further studies are needed to delineate the effects of the adsorption of other 
plasma proteins such as vWF on elastin hemocompatibility. Our current studies indicate 
that endothelialization of elastin scaffolds could be improved by activating specific 
integrin receptors on the cells thereby promoting their interaction with the substrate. 
Overall, purified elastin scaffolds displayed superior hemocompatibility than collagen 
scaffolds and with better endothelialization could become potential candidates for 
vascular replacement. 
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CHAPTER 1 - INTRODUCTION 
Cardiovascular disease is the leading cause of death worldwide as per the World 
Health Organization [1]. As of 2006, CVD accounted for 1 of every 2.9 deaths in the 
United States, amounting to approximately 34.3% of the total mortality rate [2]. Hence 
there is an overwhelming need for the development of new approaches to treat 
cardiovascular diseases and to enhance the current healthcare options.  
Biomaterials have been long used in cardiovascular applications as catheters, 
pacemakers, heart valves, stents, hemodialysis units, vascular grafts, ventricular assist 
devices and extracorporeal support systems. However, the performance of these devices 
has been significantly affected by biomaterial associated thrombosis. The associated 
complications include embolism, infarction, intimal hyperplasia, and occlusion leading to 
limited success or often complete failure of the device [3]. 
The search for the ideal non-thrombogenic material for biomaterial applications 
has been on for over three decades now. The process of blood-biomaterial interactions is 
highly complex; various factors including – platelets, plasma proteins, leukocytes, 
complement system and other mechanical factors play a significant role as described in 
Figure 1.1 [4]. Thrombosis, especially with cardiovascular devices remains a serious 
concern for long-term patency. The lack of availability of a suitable graft for small 
diameter vascular applications is partly due to the complications associated with 
thrombosis. 
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Fig 1.1: Schematic overview of the various cellular and plasma components involved in 
blood-biomaterial interactions [4]. 
The following chapter is an overview of the humoral and cellular components 
involved in the process of biomaterial-associated thrombosis and a summary of the 
various approaches currently adopted to improve the hemocompatibility of 
cardiovascular biomaterials. 
Chapter 3 outlines the basis of the research project, specific aims, and the 
relevance to the broad goal of developing a hemocompatible biomaterial suitable for 
vascular graft applications. Chapter 4 describes the materials and methods employed and 
the results of the studies are presented in Chapter 5 along with relevant discussion.  
The final chapter will summarize the observations and provide a comprehensive 
conclusion to the project with recommendations and scope for future research. 
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CHAPTER 2 – BACKGROUND 
2.1 Biomaterial associated thrombosis – role of humoral and cellular components 
2.1.1 Blood coagulation cascade 
The coagulation cascade involves a series of proteolytic zymogen-enzyme 
conversions, which are self-amplifying and ultimately result in fibrin clot formation [4, 
5]. The cascade comprises of two distinct pathways – intrinsic and extrinsic pathway.  
 
Fig 2.1: Simplistic schematic representation of the major pathways and enzymes involved 
in the blood coagulation cascade [5]. 
While the intrinsic pathway is triggered by the surface-mediated activation of 
Factor XII, the extrinsic pathway is initiated by the expression of Tissue factor (TF) by 
the damaged tissue [4]. The two pathways converge with the generation of thrombin, 
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which in turn mediates the conversion of the inactive fibrinogen to fibrin. The 
physiological relevance of the intrinsic pathway still remains under debate. However, 
there are indications of the role played by the intrinsic pathway in the propagation phase 
of coagulation, while the extrinsic pathway is responsible for its onset [4].  
A schematic representation of the cascade is represented in Figure 2.1. In-depth 
review of the underlying mechanisms of the two pathways and the various mediators 
involved is beyond the scope of this report. 
2.1.2 Plasma proteins and coagulation pathways 
As soon as a foreign material is encountered by the body, the instantaneous 
response is protein adsorption [4, 6].  Ensuing reactions such as triggering of the 
coagulation cascade, platelet adhesion and activation, largely depend on the nature of the 
adsorbed proteins on the biomaterial surface.  
The amounts of individual proteins and their conformational states are determined 
by the surface properties of the material, and these factors in turn influence the 
hemocompatibility of the material [3, 7]. Several factors including hydrophilicity or 
hydrophobicity, wettability, surface tension, charge density and smoothness have been 
implicated to play a role in modulating protein adsorption behavior [3, 7, 8]. In general, 
hydrophobic surfaces are shown to support strong interactions with adsorbed proteins. 
The heat generated during this process leads to the denaturation of these proteins 
ultimately causing conformational changes and subsequent accessibility of active sites for 
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the binding of corresponding receptors. Nevertheless, the procoagulant activity arising 
due to contact activation, is observed to be lower on hydrophobic surfaces [9]. Hence, 
more than the amount, the species and activity of specific proteins adsorbed at the 
interface, seem to modulate the biomaterial response. 
During physiological wound healing processes, platelet attachment to exposed 
subendothelium is known to be mediated by plasma proteins – fibrinogen, Von 
Willebrand Factor  (vWF) , fibronectin, thrombospondin and thrombomodulin [10]. 
Predictably, the proteins which are mainly involved in the interaction with biomaterials 
include fibrinogen, albumin, Hageman factor (Factor XII), high molecular weight 
kininogen (HMWK), collagen, fibronectin, von-Willebrand factor and these in turn are 
best studied in the context of material hemocompatibility [11-13]. 
Biomaterials are conventionally thought to set off the intrinsic pathway of the 
coagulation cascade, by causing auto-activation of Factor XII [1, 3, 5]. Negatively 
charged hydrophilic surfaces are said to increase the magnitude of this response, possibly 
by interacting with the positively charged amino acids of Hageman factor [3]. This 
activation also leads to the formation of an activation complex comprising of HMWK, 
prekallikrein and factor XI. During this process, the prekallikrein and factor XI come 
spatially closer, resulting in their reciprocal activation, further amplifying the coagulation 
response [1, 3]. HMWK actively participates in these reactions by complexation with 
prekallikrein and factor XI, thereby enabling enzymatic cleavage of these proteins by the 
activated factor XIIa. Substitution of adsorbed fibrinogen with factor XII and HMWK, 
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and subsequent activation have indeed been reported in vitro. Fibrin formation is directly 
correlated with factor XII activation. However, other evidence suggests that mere contact 
activation does not correlate with thrombin generation, indicating that contact activation 
is not the principal mechanism of biomaterial-stimulated plasma coagulation [14]. Also, 
recent studies have claimed that biomaterial-induced Factor XII activation is not surface-
specific and does not play any role in furthering the coagulation response via the intrinsic 
pathway [9, 15]. 
Fibrinogen is an important player in the adsorbed protein layer on a biomaterial 
surface and is pivotal in initiating platelet response. Materials, whose adsorbed protein 
layer is dominated by fibrinogen, tend to exhibit a higher thrombogenic potential [7]. 
Typically, hydrophilic surfaces show a lesser amount of fibrinogen adsorption as 
compared to hydrophobic surfaces. Surface adsorbed fibrinogen is known to directly 
interact with platelets by means of the membrane glycoprotein receptor GPIIb/IIIa [11]. 
In their normal state, reversible interactions are shown to prevail between the platelet 
receptors and fibrinogen. However, it is important to note that plasma fibrinogen merely 
acts as a cofactor in this process, once the platelets are already activated [8]. The 
hypothesis proposed for this phenomenon is that adsorption unmasks regions that can 
form detectable complexes with platelet receptors [8]. Fibrinogen functions in bridging 
the gap between platelets and the biomaterial surface, and also between platelets during 
secondary irreversible aggregation [4, 8]. In some studies, adsorbed fibrinogen is also 
shown to be replaced with HMWK, thereby causing contact activation, over time [4]. 
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Albumin is the most abundant protein found in plasma. It is one of the earliest 
proteins to adsorb onto a biomaterial surface, within milliseconds of exposure, owing to 
its high concentration and low molecular weight [16]. However, in most cases, albumin 
gets desorbed and substituted by other proteins that share high-affinity interactions with 
the surface, popularly known as the „Vroman effect‟[17]. Traditionally, albumin is 
considered to be non-adhesive to platelets due to the lack of established domains for 
platelet binding [18]. Many studies have proven that albumin surface-coatings confer 
superior hemocompatibility to biomaterials [19, 20]. Recent findings challenge this belief 
showing the existence of binding domains exposed due to material-mediated 
conformational changes of the protein [18]. 
2.1.3 Platelets 
Platelets are anucleated cellular fragments, derived from the megakaryocytes of 
the hematopoietic stem cell lineage. They are generally discoid in shape with a smooth 
topography. When they get activated, they become spherical and extend pseudopodia to 
adhere to the agonist [12]. The glycocalyx present covering the plasma membrane of 
platelets houses a variety of glycoproteins that act as receptors for a number of adhesive 
molecules, aggregators and procoagulant factors [8, 12]. The membrane phospholipids 
are also known to promote coagulation by the conversion of Factor X to Xa and that of 
prothrombin to thrombin [12]. The cytoplasmic contents of platelets include 
mitochondria, lysosomes, peroxisomes, dense tubular system, α-granules and electron 
dense granules [12]. These intracellular organelles contain various hydrolytic enzymes 
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and potential mediators of platelet aggregation and leukocyte stimulation [21]. The 
primary function of platelets is to prevent blood loss during injury by hemostasis [4, 12]. 
They also participate actively in wound healing processes [8]. 
Platelets are known to get easily activated when they come in contact with any 
thrombogenic surface. Several factors can act as potential agonists of platelet activation 
like, plasma proteins- fibrinogen and thrombin, exposure of collagen following vascular 
injury, subendothelial matrix components, inflammatory cytokines derived from 
leukocytes, etc.  Platelet responses can be classified into reversible and irreversible 
responses. The reversible responses include adhesion, change of shape and reversible 
aggregation , while, platelet release and secondary aggregation are irreversible [22]. 
Once platelets adhere to a biomaterial surface and get activated, a series of 
reactions follow. Bioactive compounds stored in the intracellular granules of platelets 
such as thrombospondin, β-thromboglobulin, ADP, calcium ions, serotonin, platelet 
factor 4 are released [21, 23]. Platelet factor 4 (PF4) is documented to exhibit antiheparin 
activity and thrombospondin mediates platelet-platelet recognition during secondary 
aggregation [24, 25]. P-selectin, a transmembrane glycoprotein that is present in the α-
granules of platelets, fuses with the plasma membrane, thereby expressing it on the 
surface of activated platelets [26]. P-selectin aids in low-affinity interactions between 
platelets and various leukocytes subtypes. Some amount of soluble P-selectin is also 
released during this process [4, 26]. Platelet activation also liberates arachidonic acid, 
which further results in the production and release of thromboxane B2, endoperoxides 
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and prostaglandins [4] . These released endoperoxides act as a positive reinforcement 
causing increased expression of fibrinogen receptors, promoting platelet aggregation [27, 
28]. 
Morphological changes are another hallmark response to platelet activation. 
Activated platelets show spread morphology, increasing their contact area with the 
surface, encouraging platelet-platelet interactions and aggregation. The associated 
cytoskeletal rearrangement enables centripetal distribution of fibrinogen receptors, and 
secretion of the contents of the intracellular granules [8, 12]. This rearrangement of the 
platelet plasma membrane also plays a role in providing a site for communication 
between its membrane phospholipids and complexes involved in the coagulation cascade. 
It is also believed to act as a physical barrier between the active coagulation factors and 
their native inhibitors [8].  
Platelet microparticles (PMPs) are formed by exocytotic membrane budding of 
activated platelets [4]. PMPs are formed following material-contact of blood and are 
believed to be rich in certain procoagulant factors. They help in propagation of the 
thrombotic response by adhesion to fibrinogen, fibrin and aggregation with other platelets 
[29]. 
The initial interaction of platelets with biomaterial surfaces are regulated by its 
membrane receptors.  Of the various receptors, GPIb and GPIIb/IIIa have been shown by 
several studies to have profound influence in platelet-biomaterial interactions [13, 30]. 
GPIb is a leucine-rich glycoprotein that mediates the von Willebrand factor (vWF) - 
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platelet interaction [13]. vWF is synthesized and secreted by vascular endothelial cells 
and also produced by platelets and stored in the cytoplasmic granules. Under exposure to 
shear stress due to blood flow, GPIb undergoes a conformational change, rendering it 
available for vWF binding [4]. The other receptor that is critical to biomaterial 
interactions of platelets is the constitutively expressed integrin receptor, GPIIb/IIIa. Apart 
from being expressed on the platelet membrane, these receptors are additionally stored in 
the α-granules and are translocated to the membrane during release phase of the 
intracellular substances. Normally when present, GPIIb/IIIa exists in its inactive form 
with a low-affinity binding capability for fibrinogen. The conformational shift post-
activation makes this a strong binding, ultimately leading to platelet aggregation and 
leukocyte-platelet interactions [30]. Also, other extracellular matrix components 
possessing the RGD sequence also can bind to the activated receptor.  
While it is widely believed that fibrinogen adsorption contributes majorly to 
platelet attachment, other possible in vivo mechanisms initiating this process remain 
poorly understood. It is often presumed that platelet activation with respect to 
biomaterials occurs due to thrombin generation as the culmination of the intrinsic 
coagulation pathway or by the release of ADP from stimulated blood cells [4, 6]. 
Contesting this notion, some researchers have reported failure of thrombin and kallikrein 
blockers in reducing platelet activation [31]. 
Though platelet adhesion and activation are considered to play a central role in 
the thrombotic response to biomaterials, other pathways involving complement-mediated 
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activation and platelet-leukocyte interactions have garnered interest in recent times. 
Studies have shown that inhibition of platelet adhesion or activation alone does not result 
in inhibition of the generation of PMPs or removal of platelets from circulation [4]. This 
further elucidates the need to understand that biomaterial associated thrombosis is a multi 
cell-regulated phenomenon. 
2.1.4 Role of leukocytes and complement system 
In the context of biomaterial contact, leukocytes could possibly influence a wide 
range of activities including platelet recruitment and activation, promoting further 
leukocyte adhesion and aggregation, fibrin formation and fibrinolysis [6]. Activation of 
leukocytes results in the upregulation of specific membrane receptors like CD11b and 
PSGL-1, which interact with GPIIb/IIIa and P-selectin respectively [4]. It is important to 
note that the latter two molecules are expressed in high levels on the surface of activated 
platelets. Fibrinogen is another common agonist for platelet and leukocyte adhesion to 
biomaterials. Activated leukocytes become sticky, strongly binding to damaged 
endothelial cells and material surfaces. It is also to be noted that granulocytes show 
preferential adsorption than lymphocytes, which could be explained by their endogenous 
procoagulatory effect and direct role in platelet aggregation [6]. 
The extrinsic pathway of blood coagulation initiated by tissue factor expression, 
has also been suggested to play a role following interaction with biomaterials. 
Biomaterial contact acts as a potential stimulus for TF expression by leukocytes [32]. 
This response could result in the binding of Factor X to CD11b resulting in thrombin 
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generation or assembly of the prothrombinase complex on the leukocyte cell membrane 
[4]. Another characteristic response following neutrophil and monocyte stimulation is the 
release of inflammatory and procoagulant cytokines such as – Interleukin 1 (IL-1), IL-6, 
Tumor Necrosis Factor alpha (TNF-α); arachidonic acid metabolites like leukotriene B4, 
platelet activating factor (PAF) and reactive oxygen species [4, 33]. These mediators act 
as chemoattractants for leukocytes, cause activation of platelets and also help create a 
localized microenvironment which is protected from physiological inhibitor molecules 
[4]. Interestingly, platelet release molecules earlier mentioned, promote leukocyte 
activation. This forms a network of mediators which mutually enhance the activity of the 
other cellular components involved in response to a biomaterial. 
Complement system is another important contributor in recognizing biomaterials 
as non-self and in the ensuing inflammatory response [4, 33]. It comprises of more than 
20 plasma proteins and two pathways, classic and alternate which converge into the 
common terminal pathway. Both the pathways form distinct C3 convertases, resulting in 
the production of the C3a (anaphylotoxin) and C3b. The C3b generated is involved in the 
assembly of C5 convertase, which in turn cleaves C5 to produce C5a (anaphylotoxin) and 
C5b. C5b further takes part in the formation of the terminal complement complex (TCC) 
which causes cell damage and lysis [4]. 
With regard to biomaterial-associated response, surface-induced covalent binding 
of C3b by the alternate pathway is considered most relevant. Biomaterial surfaces are 
classified as activating or non-activating based on their affinity to bind Factor B over 
13 
 
Factor H. Those surfaces which support the interaction of Factor B with the surface-
bound C3b are said to be activating, while those favoring Factor H interaction are non-
activating [33]. Some studies also report the activation of classic pathway of the 
complement system in response to certain biomaterials [34-36]. 
The complement system provides another link between the platelet and leukocyte 
response to biomaterials. The derivates of the complement-derived C3a and C5a have 
chemotactic effects on circulating monocytes and neutrophils, promote the release of 
inflammatory cytokines and lysosomal enzymes and cause aggregation of the cells [6, 
33]. These effects are attributed to the membrane expression of the alpha chain of the 
iC3b, inactive form of the C3b molecule of the complement system [33]. Inhibition of the 
complement activation in vitro has shown to significantly reduce leukocyte adhesion [37, 
38].  
Complement activation of platelets has been shown possible by several ways. 
Inhibitors of C1 complement protein which initiates the classic pathway have been 
successful in reducing platelet adhesion and microparticle release on polyethylene 
surfaces [39]. Platelets are shown to possess a receptor for C1q, which then induces P-
selectin membrane expression and GPIIb/IIIa conformational change [4, 39]. Insertion of 
TCC into platelets has also been shown to increase its procoagulant activity [4].  
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2.1.5 Role of mechanical factors 
Flow and its related parameters- wall shear stress and shear rate contribute to the 
mass transport of cells and proteins and their resultant interactions with the vessel wall or 
artificial surfaces [4, 40, 41]. Even in the absence of biochemical agonists, physical 
factors have been able to cause thrombosis. Wall shear rate can regulate reaction kinetics 
of several coagulation factors by governing the rate of removal or replenishment of the 
individual species [40]. Adhesion of platelets has shown positive correlation with shear 
rate. Similar response is also observed for Factor X activation by the TF-VIIa complex 
via the extrinsic pathway of blood coagulation [4, 40]. Conformational changes in the 
otherwise linear complex are possibly effected by flow [40] . 
On the contrary, increasing rate of shear is shown to reduce fibrin deposition [4, 
40]. In reference to thrombus formation, turbulence caused by the high shear regions is 
proposed to activate coagulation factors which deposit in the adjoining recirculation 
zones that experience low shear and promote coagulation [40]. Concentration of red 
blood cells is also believed to work in tandem with flow conditions, due to collision 
effect resulting in increased frequency of interaction with the material surface [40, 42]. 
Shear is also said to activate leukocytes, though highly dependent on testing conditions 
and materials tested [4]. 
Shear-induced activation of platelets has been reported by many groups [41, 43, 
44]. Both magnitude and duration of shear seem to play a part in platelet activation [40]. 
Upon exposure to shear, vWF binds to the activated GPIb receptor on platelets, 
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subsequent expression of GPIIb/IIIa and liberation of platelet vWF [42]. The binding 
between these two molecules results in irreversible aggregation. Furthermore, flow also 
controls the distribution of platelet release molecules which are responsible for secondary 
aggregation and setting off the coagulation response [41]. Tissue damage due to shear in 
association with platelet agonists, synergistically act to accelerate thrombotic response, 
thus making it an important factor to account for, during hemocompatibility testing of 
biomaterials [42]. 
2.2 Strategies to improve hemocompatibility of cardiovascular biomaterials 
Different approaches have been attempted to overcome the problems associated 
with thrombotic failure of cardiovascular devices. Since hemocompatibility is primarily 
modulated by the biomaterial surface rather than by the bulk properties of the material, 
introducing surface modifications to reduce thrombogenicity has been a popular option 
[16, 45]. These strategies can be broadly classified into - passivation of the artificial 
surface so as to obtain a non-reactive material that resists protein and platelet deposition; 
and biofunctionalization of the material using bioactive molecules that modify the host 
response to the material to minimize adverse effects and support functional regeneration 
[45, 46]. 
2.2.1 Surface passivation 
Both organic and inorganic materials have been studied for surface modifications 
of vascular materials. Some of the inorganic materials investigated for vascular coating 
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applications include carbon, titanium oxide and oxynitride, iridium oxide [16]. Pyrolytic 
and graphitic carbon coatings have been performed on stents and vascular prostheses, 
with improved patency initially, however with poor or insignificant reduction of 
thrombosis after long-term implantation [47]. Diamond-like carbon (DLC) coated on 
heart valves and stents, shows preferential albumin adsorption over fibrinogen but with 
an observed increase in platelet adhesion [16]. Overall, surface irregularities and 
tendency of carbide formation have been suggested for the shortcomings observed with 
carbon-based coatings [16, 47]. In comparison, hydrophilic titanium oxide coatings fare 
better with low protein adsorption, inhibition of fibrinogen activation and they are also 
reported to have anti-inflammatory properties [16]. 
 As mentioned earlier, hydrophobic materials generally show a higher protein 
adsorption and resultant conformational changes, whereas hydrophilic surfaces show 
reduced interaction with proteins. However, it must be noted that highly hydrophobic 
materials like ePTFE have been successful as vascular grafts in large diameter 
applications. Based on this general idea, hydrophilic molecules like polyethylene oxide 
(PEO), polyethylene glycol (PEG) and polysulfones have been used to modify synthetic 
polymer surfaces [1, 16, 45, 47-52]. The reduced interfacial free energy, lack of surfaces 
charges and steric repulsion are believed to be the reasons for the reduced protein 
adsorption observed with PEO [45]. Though many in vitro studies have been encouraging 
with minimal protein adsorption and platelet adhesion, in vivo results have been 
inconsistent with reference to thrombogenicity [4, 47]. Apart from functioning as non-
fouling surfaces, PEG modification has also been extended to immobilize bioactive 
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molecules as spacers, shielding the molecule from the substrate while facilitating 
interaction with the corresponding receptors [16, 49, 51, 52]. 
Albumin is another molecule which has been sought after for passivating 
biomaterial surfaces.  Being the most abundant plasma protein combined with its low 
molecular weight, it is one of the first proteins to adsorb onto any artificial surface [16].  
Early studies showed that platelet interactions were far less with albumin as compared to 
other plasma proteins like fibrinogen and immunoglobulins [47]. Ever since, attempts 
have been made to covalently link albumin directly or modify surfaces so as to support 
preferential albumin adsorption [16, 19, 47]. While in vitro studies showed significantly 
decreased platelet response, clinical studies have not been able to produce favorable 
results [20, 53]. Limitations related to direct linkage include immunological concerns, 
difficulties with sterilization and shelf life, poor control over conformational changes in 
the protein structure [16]. Additionally, some recent studies have challenged the very idea 
of albumin being non-reactive with platelets [18]. 
Yet another interesting approach is derived from the lipid bilayer structure of the 
plasma membranes of resting erythrocytes and platelets. The outer lipid layer of these 
cells have been shown to consist of the same polar head group, phosphorylcholine [54]. 
Several attempts have proven that phosphorylcholine when incorporated to biomaterials 
through in situ polymerization, ozone grafting, heat stabilization or grafting directly into 
polymer backbone, show significant reduction in protein adsorption and platelet 
attachment [47, 55]. Initial clinical studies for phosphorylcholine-coated stents have 
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reported reasonable success, however these results were not reproduced in randomized 
trials [47, 56]. Another derivative, 2-methacryloyloxyethyl phosphorylcholine (MPC) has 
been successfully used as coatings on Dacron grafts and as part of copolymers, with 
favorable results in animal studies [47, 57, 58].  
Elastin, an important structural component of blood vessels has shown to elicit 
minimal platelet response and anti-proliferative properties for smooth muscle cells [59, 
60]. These observations have inspired elastin-based surface modifications of synthetic 
materials and development of electrospun and tissue engineered scaffolds for vascular 
applications. The innate difficulty of purification, processing and insolubility of elastin 
had limited its usability [47]. However, several functional sequences have been identified 
which has led to the development of elastin-mimetic peptides, polymers, and recombinant 
elastin sequences, which are now widely being used to provide non-thrombogenic 
coatings for cardiovascular biomaterials [47, 61-63]. Elastin peptides coated using 
surface impregnation and/or passive physical adsorption has improved the performance 
of small diameter vascular grafts and catheters in both in vivo and ex vivo studies [61, 
63]. Furthermore, these surface modifications have shown to reduce the release of 
proinflammatory cytokines and inhibit smooth muscle cell migration, thereby making it 
an attractive approach to simultaneously prevent another looming problem with vascular 
devices, intimal hyperplasia [47, 59]. In addition, recent studies have also reported the 
use of elastin-mimetic triblock copolymers as protective surface coatings for small 
diameter ePTFE vascular grafts [62]. 
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2.2.2 Biofunctionalization 
The second kind of approach- biofunctionalization has employed pharmacological 
methodologies like the use of several established anticoagulants, anti-platelet drugs, 
direct thrombin inhibitors and bioactive molecules such as thrombomodulin and nitric 
oxide [1, 16, 47].  
Heparin was the first anticoagulant to be immobilized to improve 
hemocompatibility of a surface [16]. Heparin in association with antithrombin III (AT 
III) binds with high affinity to its target molecules Factor Xa and thrombin, inhibiting the 
coagulation cascade [16, 64]. It has also been found to possess anti-inflammatory 
properties [16]. The methods used for modification range from adsorption, covalent 
grafting, use of albumin-heparin conjugates to end-point immobilization, which is 
currently used clinically [16, 47, 65-67]. However, the outcomes of in vivo 
biocompatibility of heparin-coated surfaces have been mixed with some in vivo results 
showing significant improvement and others showing no difference from uncoated 
counterparts [4, 47]. One of the inherent problems associated with surface-bound heparin 
is its multi-fold reduced bioactivity in comparison with free heparin [16]. Also, the short 
half-life and inactivation by systemic administration of protamine sulfate post 
extracorporeal circulation as in the case of hemodialysis, have affected the bioactivity of 
heparin conjugated to material surfaces [16, 47].  
Other direct thrombin inhibitors both pharmacological and physiological have 
also been examined to improve biomaterial hemocompatibility. Hirudin and its 
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recombinant analogs, argatroban and benzamidine are a few inhibitor molecules which 
have been tested as surface coatings [16, 47]. Conjugation of recombinant hirudin with 
Dacron has yielded favorable in vitro and short-term in vivo results [68-70]. One 
advantage of employing direct thrombin inhibitors is that, they do not require the 
presence of antithrombin III which might be deficient in septic tissues [16]. 
Thrombomodulin is a molecule naturally produced by endothelial cells that not only 
binds to existing thrombin with high-affinity but also limits further thrombin generation 
by activation of anticoagulant protein C [16, 47, 71]. The molecule has been grafted 
covalently to polyurethane and ePTFE, and has shown promising in vitro and short-term 
in vivo outcomes [47, 72]. Nevertheless, the reduction in activity due to immobilization, 
cost factors, and unpredictable stability of conjugated thrombomodulin in vivo have 
limited its clinical applications [16, 47]. Alternatives like genetic engineering to produce 
modifiable and more stable thrombomodulin molecules are currently being explored at in 
vitro levels [73, 74]. 
Another common approach to improving biomaterial performance is the use of 
anti-platelet drugs, aimed particularly at inhibiting platelet activation and aggregation 
[16, 47]. Aspirin, an inhibitor of the production of arachidonic acid pathway platelet 
agonists, is the most widely used anti-platelet drug [47].  Inhibitors of platelet membrane 
receptor GPIIb/IIIa (abciximab) and molecules which inhibit platelet activity by 
stimulating an increase in intracellular cAMP levels including prostaglandins, 
prostacyclins, dipyridamole have also been considered for immobilization to biomaterials 
like polyurethanes, stents and Teflon grafts [47, 68, 75-77]. Aspirin-eluting materials and 
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coatings; stents coated with abciximab or releasing iloprost (prostacyclin analog) have 
shown promise with initial ex vivo and in vivo studies [75, 78-80]. However, one 
common limitation of drug-eluting or controlled release strategies is the recurrence of 
stenosis and the quantity of drug that could be loaded in the reservoir which limits the 
duration of effect [46, 47]. Nitric oxide (NO), another molecule released by vascular 
endothelium is known to be responsible for maintaining the vascular tone and 
vasodilation [71]. It has also shown to limit platelet activation and aggregation and also 
possess a negative effect on smooth muscle cell proliferation and neointimal hyperplasia 
[46, 47]. NO releasing coatings on hydrogels and films have shown release up to 2 
months in vitro [47]. But the time limitations and problems related to harmful products 
leaching out, have led to research focusing on techniques that can produce nitric oxide 
from endogenous nitrites and thiol groups [81, 82]. 
2.2.2.1 Endothelialization 
The endothelial lining which forms the blood-contacting surface of native vessels 
is the ideal, most non-thrombogenic surface known till date [1, 16, 45]. Hence, several 
efforts have been directed towards combining endothelial cells (EC) with biomaterials- 
either by means of in vitro cell seeding or by employing strategies to induce self-
endothelialization of biomaterials upon implantation [16, 46]. One significant advantage 
of this approach is the ability to create a permanently potent hemocompatible interface 
[16]. 
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Endothelial cells are known play an active role in regulating coagulation and 
thrombosis. EC synthesize a number of molecules, the relative expression of which 
governs thrombosis and fibrinolysis [71, 83, 84]. Activated EC show an upregulated 
membrane expression of TF, initiating the coagulation cascade. Apart from TF, several 
other factors such as vWF, platelet activating factor (PAF), tissue plasminogen activator 
(tPA), cell adhesion receptors are upregulated and number of other molecules including 
NO, plasminogen activator inhibitor-1 (PAI-1), thrombomodulin, prostacyclin (PGI2), 
tissue factor pathway inhibitor (TFPI) are downregulated [71, 84]. These reactions 
cumulatively, promote coagulation and activation of platelets, leukocytes and the 
complement system. However in their native state, EC possess anti-thrombotic and 
protective effects essentially by a reversal of the above mentioned trend.  
Some of the major negative feedback mechanisms of EC that control thrombosis 
are – thrombomodulin (TM) which inhibits thrombin generation, heparan sulfate bound 
to the EC membrane that binds to AT III with high affinity thereby inactivating thrombin, 
TFPI that is expressed on the EC surface and secreted extracellularly, release of 
vasoactive substances like endothelin, prostacyclin and nitric oxide which prevent 
platelet aggregation and maintain vasodilation [71, 84, 85]. All these features combined 
make endothelialization of biomaterials, an attractive approach to overcome problems 
related to hemocompatibility. It should however be noted that the endothelial cells must 
be maintained in their non-activated basal state to confer non-thrombogenicity to the 
underlying biomaterial [71] . 
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2.2.2.1.1 In vitro endothelialization 
In vitro endothelialization of biomaterials is generally a two-step procedure 
beginning with harvest of autologous cells, expansion by cell culture, and seeding 
followed by implantation [1, 16]. Adult EC, pluripotent stem cells, or endothelial 
progenitor cells (EPC) are the common cell sources for endothelialization. Since EC do 
not readily adhere to synthetic materials, they are often pre-coated with ECM molecules 
like fibronectin and collagen [16, 45, 46, 86]. Studies conducted with human umbilical 
vein endothelial cells (HUVEC) and umbilical cord-derived progenitor cells show 
successful retention of seeded ECs even after administration of shear stress [87, 88]. In 
vitro seeding of EPC also proved to increase patency of vascular grafts with enhanced 
formation of endothelial lining in vivo [89]. Other techniques like coating polymer 
surfaces with titanium carboxonitride have also yielded better EC retention [90]. Such 
endothelial cell seeded vascular materials showed reduced platelet aggregation and better 
long-term patency in animal models [83, 91, 92]. Coculture with other vascular cell types 
like fibroblasts and smooth muscle cells also improve EC attachment to artificial surfaces 
[1]. However the differences in the substrate heavily influence EC behavior in terms of 
adhesion, proliferation, differentiation and migration [71]. Neither the one or two-stage 
procedures have been successful in clinical trials with the seeded cells getting washed off 
[1]. Additionally, the cost, labor, expertise and specialized facilities required for the time-
consuming preconditioning of cells in bioreactors, potential contamination, 
uncontrollable changes in phenotype, and difficulties of obtaining enough quantities of 
autologous cells makes the in vitro approach less practical [1, 46, 85]. 
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2.2.2.1.2 In situ endothelialization 
In situ endothelialization of blood-contacting materials is an emerging strategy 
that precludes long culture times associated with in vitro cell expansion. They are also 
applicable for emergency requirements due to their immediate availability. EPC form the 
primary cell source for this approach. EPC are a small pool of cells derived from the bone 
marrow that are positive for CD133, CD34 and VEGFR-2 [85, 93]. While the latter two 
markers are retained, circulating EPC lose CD133 [93]. Therefore antibodies targeting 
CD34 and VEGFR-2 have been immobilized on stents and grafts in an attempt to home 
these progenitor cells [85, 94, 95]. Though endothelialization has been superior, adverse 
effects like intimal hyperplasia (IH) have been observed [46, 95]. This is assumed to be 
due to potential differentiation of EPC into vascular smooth muscle cell (VSMC) 
phenotype or due to the secretion of proangiogenic factors by EPC, that could support 
VSMC proliferation and migration [85, 96, 97]. Above all, the major limitation is the 
sparse number of CD34 positive cells that are EPC, and a lesser proportion that can 
differentiate into endothelial cells [98]. On the other hand, antibodies directed against 
VEGFR-2 possess good binding efficiency only at sub-arterial shear rates [85]. Current 
research is focused on conjugating VEGF to implant surfaces or use gene transfer to 
locally express VEGF (to avoid associated IH) [16, 85, 99]. One common difficulty with 
using EPC is their extremely low number in circulation. Several factors have been 
considered to improve mobilization and homing of EPC for this purpose. Pre-stimulation 
of the progenitor cells with high-mobility group box-1 (HMGB-1), leptin, stromal cell 
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derived factor -1 (SDF-1), activating integrin β2 antibody before in vivo application has 
proven successful in ensuring EPC homing to sites of injury and ischemia [85]. 
ECM molecules, ligands and peptide sequences are often used to attract EPC to a 
biomaterial. Although whole ECM molecules like fibronectin, collagen and vitronectin 
promote EC attachment; they also possess domains for interaction with platelets and 
other inflammatory cells [16, 46]. Hence, presenting specific well defined domains of 
ECM molecules to promote endothelial adhesion is a common approach for 
endothelialization. Of the synthetic peptides, the RGD sequence first identified with 
fibronectin is the most widely used. Cyclic RGD (cRGD) shows better affinity to EC and 
EPC than linear RGD, as it more closely resembles its native conformation [1, 46, 85]. 
This interaction is mediated by integrin receptors. Several integrin receptors have been 
identified on EPC as being responsible for their adhesion and migration [46]. 
Incorporation of cRGD as a stent coating has shown improvement in endothelial cell 
recruitment both in vitro and after 12 weeks of in vivo implantation [100]. Interestingly, 
cRGD also acts as an antagonist for platelet membrane receptor GPIIb/IIIa [46, 101]. One 
potential limitation of this approach could be the presence of RGD-binding domains on 
other plasma proteins and cells, which can competitively bind to the peptide interfering 
with EPC capture [85]. Laminin-derived YIGSR peptide has been combined with PEG 
and NO to improve long-term patency of polyurethane grafts [102, 103]. 
Using magnetic labeling to home EPC has been tried with metallic stents and 
magnetized grafts [104, 105]. This process involves the in vitro culture of isolated EPC, 
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labeling with superparamagnetic microspheres followed by in vivo application [85, 105]. 
Though this method will offer well characterized EPC, it is a time and labor-intensive 
approach, whose potential long-terms effects are largely unknown [85]. Another novel 
approach proposes the use of aptamers, single-stranded nucleic acid sequences [1, 85]. 
These molecules can be selected with high specificity in vitro, can bind to cell-specific 
target sequences and also resist non-specific protein adsorption [85, 106]. Their efficacy 
as capture molecules has been demonstrated in vitro under shear [107]. In vivo 
performance of aptamers in homing EPC remains to be evaluated. 
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CHAPTER 3 – PROJECT RATIONALE 
Elastin is the principal ECM component of the muscular medial layer of the 
vessel wall. It has been shown to be thromboresistant and has anti-proliferative properties 
for smooth muscle cells [59, 60]. Hence, it could potentially be a valuable material for 
substituting currently used synthetic grafts, especially in small diameter vascular 
applications, where synthetic grafts have shown limited success due to complications 
associated with thrombotic failure and intimal hyperplasia. Elastin-based and elastin-
mimetic coatings have recently been investigated for their potential to improve 
biomaterial hemocompatibility, although clinical studies are yet to be conducted [47, 61, 
62]. 
In our laboratory, we have earlier developed a purified elastin scaffold for 
vascular tissue engineering, derived from porcine tissue [108]. The scaffold offers the 
advantages of maintaining the native structural architecture of the vessel wall, provides 
good mechanical properties like compliance and porosity required for cellular infiltration 
and subsequent remodeling [109-111].  
The broad objective of the present study is to study the platelet response and 
integrin-mediated early endothelial adhesion to purified elastin scaffolds. Any material 
used for blood-contacting applications should be tested for its hemocompatibility. 
Platelets play a central role in hemostasis and resulting thrombus formation; therefore 
platelet response to biomaterials needs to be studied for cardiovascular applications. 
Several groups have used platelet adhesion and activation profiles to assess the 
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hemocompatibility of biomaterials [12, 41, 65-67, 81, 112-115]. Other significant factors 
such as presence of plasma proteins and shear have also been incorporated into in vitro 
hemocompatibility testing systems [41, 64, 65, 116, 117]. 
Various methods have been investigated to improve the hemocompatibility of 
existing materials. Among them, promoting endothelialization is widely researched [46, 
85, 89, 93]. Different ways to enhance adhesion and retention of endothelial cells using 
ECM ligands and peptides for EC membrane receptors are being studied in this context 
[100, 102, 103, 118]. Hence, minimizing platelet response and encouraging endothelial 
attachment could lead to improved biomaterial hemocompatibility.  
Specific aims 
Aim 1: To study platelet behavior on purified elastin scaffolds. 
We would characterize platelet attachment and activation to tissue engineered 
elastin scaffolds using lactate dehydrogenase (LDH) assay and Scanning Electron 
Microscopy (SEM). Collagen scaffolds, also purified from porcine carotid arteries would 
be used as the positive reference material, since both are porous, protein-based, tissue 
engineered matrices thereby being highly relevant to study their comparative response. 
The significance of factors such as scaffold dimensions and porosity, plasma proteins and 
shear would be analyzed with respect to platelet behavior to our scaffolds. We also intend 
to understand how plasma proteins respond to the two different scaffolds by evaluating 
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plasma recalcification and also by studying surface-specific adsorption using Circular 
Dichroism. 
Aim 2: To investigate endothelial cell retention and attachment to tissue engineered 
elastin scaffolds. 
We would study the retention of endothelial cells seeded on elastin scaffolds 
under static and shear conditions at early time points. Also, since integrins are the 
membrane receptors primarily involved in EC adhesion to ECM molecules, we intend to 
study the role of specific integrin receptors in mediating adhesion to tissue engineered 
elastin scaffolds. We would evaluate the role of individual receptors in contributing to 
early-adhesion of endothelial cells to the substrates, as this is considered critical for 
maintaining non-thrombogenicity of the underlying material. The pattern of the relative 
importance of the different integrin receptors would be compared to collagen and plain 
tissue culture polystyrene. The knowledge obtained from this study could then be used to 
activate specific receptors on the endothelial cells to improve adhesion onto elastin 
scaffolds or even incorporate, increase the spatial distribution of well-defined ligands for 
specific integrin receptors for better attachment and retention of seeded endothelial cells 
on biomaterial surfaces. 
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CHAPTER 4 – MATERIALS & METHODS 
4.1 Preparation of 3D elastin scaffolds 
Porcine carotid arteries were obtained from Animal Technologies Inc., Tyler, TX, 
washed first with saline and rinsed thoroughly in PBS. The arteries were cleaned off the 
excess fat, surrounding fibrous tissue and then rinsed with PBS.  Purified elastin scaffolds 
were obtained by cyanogen bromide (CNBr) treatment [119]. Briefly, arteries were 
allowed to stir in a solution of 70% formic acid (v/v) containing 50 mg/mL of cyanogen 
bromide for 24 hours (both chemicals were obtained from Acros Organics, Morris Plains, 
NJ). The treated arteries were heated at 60
o
C for 1 hour followed by boiling for 5 minutes 
to inactivate CNBr. The purified elastin scaffolds were washed extensively in 70% 
ethanol (v/v) to remove the residual acid and stored in 70% ethanol. 
4.2 Preparation of 3D collagen scaffolds  
Carotid arteries obtained from the same source, were first decellularized, 
crosslinked and then elastin was removed to give purified collagen scaffolds, as described 
by Lu et al [108]. Decellularization was performed using sodium dodecyl sulfate (SDS) 
followed by trypsin digestion. Arteries were incubated in 1% SDS (w/v) solution in 10 
mM Tris buffer (pH 8) for 4 days at room temperature. Samples were rinsed twice with 
Tris buffer, and digested with 0.05% trypsin (w/v) (Sigma-Aldrich Corp., St. Louis, MO), 
0.1% ethylenediaminetetraacetic acid, EDTA (w/v) in 10 mM Tris buffer, pH 8, for 18 
hours at 37
o
C. The second step of crosslinking was done using 20 mM 1-ethyl-3-(3-
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dimethylaminopropyl) carbodiimide (EDC) and 10 mM N-hydroxy succinimide (NHS) 
(Thermo Fisher Scientific, Rockford, IL) in 50 mM Hepes buffer at pH 6.5 at room 
temperature for 72 hours. Samples were later rinsed with 100 mM NaH2PO4 to quench 
residual EDC. Finally, elastin was removed by elastase digestion. 20 U/mL elastase 
(Elastin Products Company Inc., Owensville, MO) solution was prepared in 100 mM Tris 
buffer (pH 7.8) containing 1 mM calcium chloride and 0.02% sodium azide (w/v). 
Decellularized and crosslinked artery samples were incubated at 37
o
C for 4 days. All 
steps were done with gentle shaking and using 4 mL solution per cm
2
 of artery, but for 
the elastase digestion for which 2 mL solution was used per unit area. Purified collagen 
scaffolds thus obtained were rinsed well and stored in 70% ethanol (v/v). Also, the 
scaffolds were punched into desired sizes (to fit into 96-well microplate) before digestion 
with elastase. 
4.3 Characterization of 3D scaffolds 
4.3.1 Histology 
Fresh carotids, purified collagen and elastin scaffolds were embedded in OCT 
(Tissue-Tek - Electron Microscopy Sciences, Hatfield, PA) and cryosections of 6 µm 
thickness were obtained. Masson‟s trichrome and Verhoff‟s Van Giesen (VVG) staining 
was performed to confirm decellularization and the presence of purified collagen and 
elastin respectively. Additionally, removal of glycosaminoglycans (GAG) and 
decellularization was checked by alcian blue staining on elastin scaffolds. All sections 
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were fixed in 95% ethanol (v/v) for a minute and washed in distilled water before 
staining. 
For Masson‟s trichrome, samples were first fixed in Bouin‟s fixative and then 
successively stained in Weigert‟s Iron hematoxylin, Biebrich scarlet acid fuchsin and 
counterstained with light green S.F yellowish solution. For VVG staining, sections were 
placed in Verhoff‟s working solution, followed by ferric chloride treatment and 
counterstained with Van Giesen‟s solution. All staining solutions were obtained from 
Poly scientific, Bay Shore, NY. 
In the alcian blue method, fixed samples were stained with 1% alcian blue (w/v) 
solution in 3% acetic acid (v/v) (pH 2.5) and counterstained with nuclear fast red. All 
slides were coverslipped with Permount (Fisher Scientific Inc., Pittsburgh, PA) and 
observed under the microscope (Zeiss Inc.). 
4.3.2 DNA quantification assay 
The removal of DNA from the purified elastin and collagen scaffolds was 
confirmed quantitatively by the DNeasy blood & tissue kit (Qiagen Inc., Valencia, CA) 
as per the manufacturer‟s protocol. Briefly, samples of fresh carotids and purified protein 
scaffolds were cut into small pieces and incubated in buffer containing proteinase K 
overnight at 56
o
C with gentle shaking (n = 4 per group). DNA was purified using a 
column separation method and the absorbance measured at 260 nm in a UV/Vis 
33 
 
spectrophotometer (Bio-Tek Instruments Inc., Winooski, VT). DNA quantity was 
calculated as per the given instructions. 
4.4 Preparation of collagen and elastin 2D scaffolds 
Collagen and elastin two-dimensional scaffolds were prepared on glass coverslips 
(Electron Microscopy Sciences Inc., Hatfield, PA) 5 mm in diameter that fit into 96-well 
microplates. The glass coverslips were thoroughly washed with piranha solution (70% 
sulfuric acid and 30% hydrogen peroxide, both (v/v)) followed by a modified RCA 
(Radio Corporation of America) basic wash (1:1:3 v/v NH4OH:H2O2:H2O) to remove 
both organic and inorganic impurities, sonicated in ethanol and blow-dried with N2 
before coating with collagen or elastin peptides.  
Rat tail tendon type I collagen (BD Biosciences, San Jose, CA) diluted in 0.02 N 
acetic acid was coated at a concentration of 1 mg/mL for 1 hour at room temperature. The 
coverslips were then washed thrice with PBS to remove excess acid. Elastin peptides 
(Elastin Products Company Inc., Owensville, MO) which contains a random mixture of 
peptides with the functional VGVAPG sequence, was dissolved in 0.01 N sodium acetate 
buffer (pH 5) containing 0.05% sodium azide (w/v), at a concentration of 10 mg/mL. The 
coverslips were incubated in this solution for 1 hour at 37
o
C and allowed to dry overnight 
in a sterile hood. It is important to mention that for the platelet attachment studies, the 2D 
surface coatings were directly laid on the surface of the TCPS well plate. 
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4.5 Characterization of 2D scaffolds 
4.5.1 Contact angle analysis 
The air-water contact angle of the coated and the uncoated coverslips was 
measured with a CAM 200 optical contact angle/surface tension meter (KSV Instruments 
Ltd.). The plain, collagen and elastin peptide coated coverslips were mounted on the 
stage and contact angle obtained by dropping nanopure water on the surface. At least 
three measurements were taken per group.  The protein-coated coverslips were washed 
twice with distilled water and blow-dried prior to taking readings, to get rid of non-
specifically adsorbed surface impurities. Another set of measurements were also taken for 
the protein-coated samples, after hydration with nanopure water for an hour, to confirm if 
the adsorbed proteins were retained on the glass surface. 
4.6 Preparation of platelet suspensions 
Whole blood (30 mL) was collected from healthy volunteers by standard 
venipuncture procedure at the Redfern Health Center. It was made sure that all blood 
donors were not under any medication for at least a week prior to withdrawal. Blood was 
collected in BD Vacutainers containing acid citrated dextrose (ACD) (Becter-Dickinson, 
Franklin Lakes, NJ) and transported to the laboratory on ice. The first few mL of blood 
obtained was discarded as they tend to be high on clotting factors that may interfere with 
platelet studies. All protocols for participation of human subjects were approved by the 
Institutional Review Board at the University. Platelet suspension buffer (PSB) was 
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prepared with a composition of 137 mM NaCl, 2.7 mM KCl, 5.5 mM dextrose, 10 mM 
Hepes, 0.4 mM NaH2PO4 and 0.1 U/mL apyrase (Sigma-Aldrich Inc., St. Louis, MO) . 1 
mM MgCl2 and 2.5 mM CaCl2 was added to the PSB prior to platelet experiments to give 
appropriate metal ion concentrations. 
Blood was centrifuged (Allegra 6R, Beckman Coulter, Fullerton, CA) at 1200 
rpm for 15 minutes to separate platelet rich plasma (PRP) from the cellular components. 
PRP was carefully separated and the concentration of platelets present was measured 
using a particle count analyzer (Beckman Coulter, Fullerton, CA). The PRP obtained was 
used for platelet studies at a concentration of 1x10
8
 cells/mL. Platelet suspension buffer 
(PSB) with the metal ions, at pH 7.4 was used to dilute the PRP to the desired final 
concentration. 
Washed platelets (WP) suspension was prepared using a gel separation technique. 
A liquid chromatography column made up of Sepharose 2B (Sigma-Aldrich Inc., St. 
Louis, MO) was allowed to equilibrate with PSB. PRP was pipetted into the column and 
buffer was allowed to flow through from a reservoir. Platelets being the high molecular 
weight components separated out first and were collected in microcentrifuge tubes. The 
turbid solution was collected until proteins separated out, indicated by a change in color 
of the solution. The platelet count in the pooled solution was measured and made up to a 
working concentration of 1x10
8
 cells/mL. 
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4.7 Platelet studies 
Prior to platelet studies, the purified 3D elastin and collagen scaffolds were 
punched into circular discs that fit into 96-well microplates. The scaffolds were washed 
thrice with PBS and stored overnight in PBS before the experiments. Glass coverslips 
treated with Sigmacote (Sigma-Aldrich Inc., St. Louis, MO) was used as the negative 
control while collagen acted as the positive control. In case of 2D scaffolds, collagen and 
elastin peptides were directly coated on TCPS and glass-coated with sigmacote served as 
the negative control.  
Orbital shear was provided using an orbital plate shaker (VWR, S-500) calculated 
using the equation, 
Τmax = a √ ηρ (2πf)
3
 
(a- radius of gyration of the shaker (cm), ρ- density of solution (g/mL), η- viscosity at 
37°C (poise) and f- frequency of rotation (rps)). Frequency of 250 rpm, as per the above 
equation corresponded to a maximal shear stress of 12.7 dynes/cm
2
, comparable to 
arterial shear levels. 
4.7.1 Lactate dehydrogenase assay 
Platelet attachment was studied using lactate dehydrogenase (LDH) quantitative 
assay (CytoTox® Non-radioactive Cytotoxicity assay, Promega Corp., Madison, WI). 
100 µL PRP or WP was added to each sample (n= 4-6 per group) and allowed to interact 
with the sample under static or shear conditions for 15, 60 minutes at 37
o
C. After 
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incubation, the non-adherent platelets were removed by at least three washes with PBS. 
100 µL PBS was added to each sample and adherent platelets were lysed with a lysis 
buffer. The amount of LDH present in each sample was measured following an enzyme-
substrate specific colorimetric reaction. Absorbance was measured at 490 nm in a 
UV/Vis spectrophotometer (Bio-Tek Instruments Inc.) and the number of attached 
platelets was quantified using a standard curve constructed with samples of known 
platelet numbers. 
4.7.2 Scanning Electron Microscopy 
Platelet activation was studied by Scanning Electron Microscopy (SEM) with n=3 
samples per group. Two and three dimensional scaffolds of elastin and collagen were 
treated with 100 µL of either of the platelet suspensions (PRP or WP) under static or 
dynamic conditions for one hour at 37
o
C. Non-adherent cells were washed off with PBS 
thoroughly and the samples were fixed in Karnovsky‟s fixative containing 2.5% 
glutaraldehyde (v/v) and 2% formaldehyde (v/v) in 100 mM sodium cacodylate (Electron 
Microscopy Sciences, Hatfield, PA) at pH 7.4 for 30 minutes at room temperature and 
rinsed again in PBS. Following this step, dehydration of the samples was performed 
using an ascending percentage-graded series of ethanol-water mixtures (50%, 60%, 70%, 
80%, 90% and 100% (v/v)), for 10 minutes each. 20 µL of hexamethyldisilazane 
(HMDS) (Sigma- Aldrich, St. Louis, MO) was added to each sample and allowed to dry 
overnight in a chemical fume hood. Samples were observed using FESEM-Hitachi S4800 
scanning electron microscope and images were taken. The morphology of the platelets 
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adhered was graded as described by Goodman et al on a five-point scale of increasing 
activation namely – round, dendritic (with early pseudopods), spread dendritic, spread 
and fully spread [120]. 
4.8 Measurement of plasma recalcification time 
For measuring the clotting time of recalcified plasma, platelet poor plasma (PPP) 
was prepared by centrifuging PRP at 700g for 15 minutes and collecting the resulting 
supernatant. 100 µL of PPP was added to elastin and collagen 3D scaffolds placed in 2 
mL microcentrifuge tubes (n=5 per group) and incubated at 37
o
C for 1 minute. 100 µL of 
25 mM CaCl2 was then added and the solution was constantly monitored for the 
formation of fibrin threads by dipping a stainless-steel loop coated with silicone [121].  
The first instance of fibrin formation was recorded as the clotting time. Standard glass 
coverslips were used as the baseline control.  
4.9 Protein adsorption on elastin- and collagen-coated substrates 
Quartz slides (0.375” x 1.625” x 0.0625”, Chemglass) were cleaned with piranha 
solution, followed by a modified RCA acid wash (1:1:3 v/v HCl: H2O2: H2O), sonicated 
in ethanol and dried using N2 gas. The cleaned substrates were then coated with elastin 
peptides or with rat tail tendon type I collagen, as described previously. 
The protein-coated surfaces were washed with distilled water to remove loosely 
bound protein and other impurities. Background Circular Dichroism (CD) and 
absorbance spectra for the collagen- and elastin-coated substrates were first obtained. The 
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slides were fully immersed in 25 mM potassium phosphate buffer (pH 7.4) in a four-well 
plate and a suitable volume of fibrinogen (FIB3, Enzyme Research Laboratories, South 
Bend, IN) depleted in Von Willebrand factor and fibronectin was added from the stock 
solution to give a physiologically relevant bulk concentration of 3 mg/ml. Care was taken 
to ensure that the protein was added below the air-water interface, to avoid denaturation 
of the protein. The slides were incubated in fibrinogen (Fg) solution for 1 hour at 37°C. 
After incubation, an infinite dilution step was performed to remove all the loosely bound 
and unadsorbed fibrinogen from the solution and also to avoid contact of the substrate 
with the denatured protein which may be present at the interface, had this dilution step 
not been performed. Finally, the slides were washed in nanopure water and taken for CD 
measurements to analyze the secondary structure of the adsorbed Fg. 
4.10 Circular dichroism  
The conformation of native and adsorbed fibrinogen (Fg) was studied by circular 
dichroism spectropolarimetry using a Jasco J-810 spectropolarimeter (Jasco Inc, Easton, 
MD) at room temperature. The native structure of Fg in solution was determined first, 
using a special high-transparency quartz cuvette (Starna Cells, Inc., Atascadero, CA) with 
a path-length of 0.1 mm. Fibrinogen was diluted from the stock to a known concentration 
using a 25 mM potassium phosphate buffer, pH 7.4.  The background spectra consisting 
of buffer alone in the cuvette was measured, followed by the Fg solution. This 
background spectrum was later subtracted from the protein spectrum to account for the 
buffer effects.  
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The CD and absorbance spectra thus obtained were interpreted as described by 
Sivaraman et al [122, 123]. The ellipticity (in mdeg) was converted to molar ellipticity 
(deg•cm2/dmol) by the following equation, 
[θ] = (θ • Mo)/(10,000 • Csoln • L)  (1) 
where [θ] is molar ellipticity, θ is ellipticity in mdeg, Mo is the average residue molecular 
weight (118 g/mol), Csoln is the Fg solution concentration (g/mL) and L is the path length 
of the cuvette (cm). 
Since proteins have been shown to exhibit a peptide absorbance peak at 195 nm, 
the height of this peak (A195) was used to construct a calibration curve of A195 vs. Csoln for 
different serial dilutions of Fg of known concentration [122, 124]. From Beer- Lambert‟s 
law we have,  
A195 = εprotein • Csoln • L   (2) 
where εprotein is the extinction coefficient of the protein in mLg
-1
cm
-1
 (or cm
2
/g), and L is 
the path-length of the cuvette. The slope of the above mentioned calibration curve is 
represented by the “εprotein • L” term from eq. 2.  
It is important to note that the term “Csoln • L” term in eq. 1 has units of g/cm
2
, 
which is equivalent to the units for the surface concentration of the adsorbed protein. 
Based on the assumption that the absorbance of a protein is dependent on its mass per 
unit area in the path of the of the light beam, irrespective of whether the protein is in its 
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solution or adsorbed state, the calibration curve of A195 vs. Csoln may also be utilized for 
calculating the surface coverage of adsorbed Fg (Qads) [123]. 
Hence, the “Csoln • L” term in eq. 1 can be replaced by Qads, to yield the following 
equation which was used for calculating the molar ellipticity of the adsorbed Fg, 
[θ] = (θ • Mo)/(10,000 • Qads)   (3) 
At least three different measurements were taken for each substrate  and the molar 
ellipticity vs. wavelength data obtained from the CD measurements were deconvoluted 
using the SP-22X algorithm and analyzed using SELCON software package to give 
percentage α-helix and β-sheet content of native and adsorbed Fg. 
4.11 Cell culture 
Human umbilical vein endothelial cells (HUVEC) were procured from Life 
Technologies Corp. Carlsbad, CA and cultured in Medium 200 supplemented with 
LSGS- low serum growth supplement. Cells between passage numbers of 3 and 7 were 
used in all the studies. Scaffolds used for endothelial cell studies were washed three times 
with PBS and stored overnight in PBS. In addition, they were incubated in serum free 
media for at least an hour before cell seeding. 
4.12 Endothelial cell retention studies 
To observe early time-point endothelial cell retention on three-dimensional elastin 
scaffolds under static and dynamic conditions, LDH assay (CytoTox® Non-radioactive 
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Cytotoxicity assay, Promega Corp., Madison, WI) was used. Briefly, HUVEC were 
trypsinized, suspended in serum free media and seeded at a concentration of 20,000 
cells/cm
2
 on elastin scaffolds and placed in the incubator at 37
o
C, 5% CO2 for 10, 30 
minutes under static or shear conditions. Plain TCPS served as the baseline control and 
n= 4-5 samples were used per group. Unattached cells were washed off and cell retention 
was quantified by measuring the levels of LDH in the sample, as previously described. A 
standard curve constructed with known cell numbers was used to quantify the results 
obtained. 
4.13 Adhesion inhibition assay 
Adhesion inhibition assays were aimed at identifying the integrin receptors which 
play a role in cell adhesion to purified elastin scaffolds. TCPS served as the baseline 
control while collagen (PureCol from Inamed Biomaterials, Fremont, CA) was used as 
the positive control. 8 parts of chilled PureCol was mixed with 10X PBS buffer, adjusted 
the pH to 7.4±0.2 and allowed to gel in 96-well microplates. The gels formed were dried 
overnight to obtain a uniform coating of collagen on the TCPS substrate. The films were 
washed with distilled water to remove any precipitated salts and to rehydrate the collagen 
prior to cell seeding. Three distinct inhibitory antibodies were used, directed against the 
αv (Anti-human integrin αv Mouse mAb (272-17E6), Calbiochem- EMD, La Jolla, CA), 
α4 (Mouse anti human CD49d (HP2/1), Serotec, Raleigh, NC) and β1 (Mouse anti-
human integrin β1 mAb (P4C10), Chemicon- Millipore, Billerica, MA) integrin receptors 
and a no antibody group served as the internal control (n = 4-6 per group). 
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The scaffolds were incubated in serum free media for at least an hour before the 
experiment. HUVEC suspended in serum free media were seeded on the substrates at a 
concentration of 20,000 cells/cm
2
, since serum proteins can potentially interfere with/ 
enhance cellular attachment. Simultaneously, the inhibitory antibodies were also added in 
a ratio of 1:1 by volume. The cells were incubated with the substrate for 30, 45 and 60 
minutes under static conditions in a sterile incubator at 37
o
C, 5% CO2.  
At the end of the incubation period, cellular attachment in response to inhibition 
of specific integrin receptors was analyzed using the quantitative, colorimetric lactate 
dehydrogenase assay (CytoTox® Non-radioactive Cytotoxicity assay, Promega Corp., 
Madison, WI). Cellular attachment was expressed as relative percentage attachment, 
normalized to the no antibody control group for each substrate. 
4.14 Statistical analysis 
All statistical analysis was performed by single-factor analysis of variance 
(ANOVA) and the values expressed in terms of mean ± standard error of the data points 
within the group.  p ≤ 0.05 was considered statistically significant. 
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CHAPTER 5 – RESULTS AND DISCUSSION 
5.1 Characterization of 3D scaffolds 
5.1.1 Histology 
The purity of 3D collagen and elastin scaffolds prepared was confirmed by 
Masson‟s trichrome and VVG staining. Fresh carotids were used as positive controls.  
 
     
   
Fig 5.1: Histological sections of (A) fresh carotids, (B) collagen and (C) elastin scaffolds 
stained with VVG which stains collagen red-pink and elastin fibers black in color. 
Original image magnification – 100X. 
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With VVG staining (Figure 5.1), fresh arteries showed characteristically stained 
black elastic fibers and the collagen stained red to pink in color. The elastin scaffolds 
prepared by CNBr treatment showed dense black fibers confirming that purified elastin 
was retained with the complete removal of collagen. On the other hand, collagen 
scaffolds showed a light pink staining with black fibers being visibly absent.  
Furthermore, alcian blue staining was performed to confirm complete removal of 
GAG and cellular material (Figure 5.2). It was seen that purified elastin scaffolds were 
completely devoid of nuclei (counterstained with nuclear red). Also, GAGs that stained 
blue in the fresh tissue were absent in the elastin scaffolds. 
    
Fig 5.2: (A) Fresh carotids stained with alcian blue showing GAG stained blue and nuclei 
stained deep pink and (B) elastin scaffolds showing removal of GAG and cellular 
contents. Image original magnification – 100X.  
Similarly, collagen scaffolds were characterized by Masson‟s trichrome staining 
(Figure 5.3). Pure collagen scaffolds stained green while the elastin scaffolds stained a 
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pale red. Fresh tissue showed typical green-stained collagenous connective tissue and 
muscle fibers stained red. 
 
    
Fig 5.3: (A) Fresh carotids, (B) collagen and (C) elastin scaffolds stained with Masson‟s 
trichrome staining collagen green and muscle fibers red. Original image magnification – 
100X. 
5.1.2 DNA quantification assay 
DNA quantification showed that approximately 97.5% of the total DNA content 
was removed in the elastin scaffolds, thus proving the effectiveness of the cyanogen 
bromide treatment (Figure 5.4).  
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Fig 5.4: DNA quantification analysis confirms decellularization of elastin scaffolds, as 
compared to native artery (n=4 per group);  (*) denotes p ≤ 0.05. 
However, the collagen scaffolds showed abnormal values of absorbance (even 
higher than the fresh artery). We assume that the various steps and agents involved in 
processing the collagen scaffolds could possibly interfere by absorbing light in the UV 
region, as histological evaluation showed preservation of purified collagen with the 
complete elimination of cells and other ECM components. Corroborating this view, 
literature reported considerable absorption of EDC (used to crosslink the collagen 
scaffolds) in the UV region [125]. Hence unreacted and/or unquenched residual EDC 
present could be the potential source for this observed anomaly. 
5.2 Characterization of 2D scaffolds 
5.2.1 Contact angle measurement 
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Contact angle measurement is a simple technique to understand surface 
characteristics of a material. This angle gives a measure of wettability which is a 
characteristic of every substrate. 
Type of substrate Contact angle (in deg) 
Plain glass 15.66 ± 1.33 
Collagen Before hydration 38.88 ± 2.80* 
After hydration 40.71 ± 1.56* 
Elastin 
peptides 
Before hydration 37.13 ± 1.55
 
After hydration 48.39 ± 1.94
 
Table 5.1: Air-water contact angles measured on elastin and collagen-coated glass 
coverslips; Values with p ≥ 0.05 are marked with (*). 
Results obtained from measuring the air-water contact angle for cleaned and 
uncoated glass surfaces were significantly different from the values obtained for both 
elastin- and collagen-coated coverslips (Table 5.1). We also measured the contact angles 
of the protein coated coverslips after keeping them in distilled water for 1 hour 
(hydration) to check if the coated protein layer remained intact. Following this, the 
coverslips were dried and contact angle was measured.  
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Glass coverslips cleaned with piranha became highly hydrophilic as expected 
[126, 127]. Collagen-coated glass coverslips were moderately hydrophilic, comparable to 
values reported in literature [128, 129]. This value did not vary significantly, before and 
after hydration, thereby confirming that the collagen coating was well-preserved. Glass 
coverslips coated with elastin peptides also showed contact angles similar to collagen-
coated substrates. Unlike in the case of collagen, there was a notable increase in the 
contact angle of elastin-coated coverslips after treating with water. Since this value was 
also significantly different from that for uncoated glass, it would be safe to assume that 
the integrity of the coating was not compromised. 
It should be noted that the elastin peptides used were a mixture of peptides of 
different molecular weights ranging between 1-60 kDa, containing the functional 
VGVAPG sequence of elastin. Hence structurally, they are very different from the native 
insoluble, mature, and highly hydrophobic elastin. Also, the charges present at the ends 
of each peptide chain can favorably interact with the hydrophilic glass substrate. Hence, 
we observe moderately hydrophilic values for the air-water contact angle of elastin-
coated coverslips, before hydration. 
Water molecules from the bulk solvent can interact with the elastin polypeptide 
chain and its tightly associated hydration shell, resulting in increased mobility of the 
chains [130]. This could lead to an increased interaction and subsequent clustering of 
hydrophobic residues. Also the hydration water in itself contributes to the elasticity of 
elastin [130, 131]. Such interactions between water molecules and the adsorbed elastin 
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peptides could potentially explain the observed increase in contact angle for elastin-
coated substrates after the hydration step. In addition, it is also possible that small 
molecular weight peptide chains were washed off during hydration, leaving behind larger 
peptides making the substrate more hydrophobic. 
5.3 Platelet studies 
Platelet adhesion and activation are important events that eventually lead to 
biomaterial associated thrombosis. In vitro hemocompatibility studies hence assess 
platelet response to biomaterials to investigate their thrombogenicity. The behavior of 
platelets with an artificial surface can be highly influenced by the presence of plasma 
proteins and hemodynamic factors such as shear stress. 
Earlier studies have shown that elimination of plasma proteins or use of 
suspension media other than plasma significantly alters platelet response to test materials 
[132, 133]. Similarly, it is important to include shear stress while evaluating 
hemocompatibility of materials since thrombus formation in vivo occurs under flow 
conditions. The mechanism of shear-mediated platelet response is primarily transduced 
by means of plasma proteins [134]. Therefore both plasma proteins and shear must be 
incorporated to truly evaluate the performance of blood-contacting biomaterials. In the 
present study, we attempt to delineate the effects of these two major factors in 
influencing the behavior of platelets in response to purified elastin and collagen scaffolds, 
in an in vitro testing system. 
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Different systems such as cone and plate rheometer, parallel plate flow systems, 
orbital shaker etc. have been used to test materials under shear. While parallel plate 
chambers simulate laminar shear conditions, it must be noted that flow conditions under 
pathological conditions or at anastomotic sites are often disturbed and non-laminar. 
Hence in this study we chose the orbital shaker system to study the influence of shear on 
platelet interactions with the substrate [135, 136]. This setup is inexpensive, does not 
require high volumes of platelet suspensions (as opposed to the parallel plate flow 
chamber) and models disturbed flow patterns that the biomaterial will be exposed to 
immediately post implantation. 
5.3.1Quantification of platelet attachment (LDH assay) and morphological analysis of 
platelet activation (SEM) 
For the platelet attachment studies, sigmacote-treated glass coverslips were used 
as negative control and showed negligible amounts of platelet attachment both with 
platelet rich plasma (PRP) and washed plateletsuspension (WP). All statistical analysis 
were performed between collagen and elastin samples (that were tested under the same 
mechanical conditions, with the same platelet suspension and for the same duration) and 
p ≤ 0.05 was considered significant.  
All SEM studies were performed at the end of a 60 minute incubation of the 
substrate with the platelet suspension, since we were interested in studying platelet 
response to the scaffolds after allowing them to interact for the longest test period.  
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5.3.1.1 Platelet attachment on 3D elastin and collagen scaffolds 
 
Fig 5.5: Platelet attachment with PRP on elastin and collagen 3D scaffolds after (A) 15 
minute and (B) 60 minute incubation showing lower platelet attachment on elastin 
scaffolds (* and # represent p ≤ 0.05). 
As presented in Figure 5.5, with PRP there was no significant difference in 
platelet attachment between elastin and collagen at 15 minutes under static conditions. 
But after 60 minutes incubation, the difference was marked. When the scaffolds were 
tested under shear, elastin supported much less adhesion as compared to collagen, both 
after 15 and 60 minutes incubation indicating its superior platelet-resistant properties. 
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While platelet attachment levels did not vary between static and shear conditions 
for collagen, elastin samples tested under shear showed a much reduced number of 
attached platelets. This could be explained by the reduced interaction time for platelets 
with the substrate under dynamic testing conditions when compared to a static testing 
system. Since shear is known to cause conformational changes of platelet receptors 
leading to platelet binding to collagen [134], the influence was higher in collagen while 
elastin‟s lack of receptors for platelet binding caused no increase in platelet binding under 
shear.  
 
Fig 5.6: Platelet attachment with WP on elastin and collagen 3D scaffolds after (A) 15 
minute and (B) 60 minute incubation showing similar platelet behavior on collagen and 
elastin when plasma proteins are removed. (# represents p ≤ 0.05). 
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In the absence of plasma proteins, there was almost no difference in the behavior 
of elastin and collagen scaffolds with respect to platelet attachment (Figure 5.6). Elastin 
scaffolds showed a higher number of adhered platelets with WP than with PRP, both 
under static and dynamic conditions. This could be attributed to the absence of plasma 
proteins which would initially adsorb on the elastin surface. Since elastin probably does 
not cause any structural rearrangements in these proteins, platelets interacted poorly with 
the substrate when plasma proteins were present. However when this component was 
removed, non-specific weak interactions could be possible with the underlying elastin 
substrate. 
For collagen scaffolds, the number of platelets attached with WP under static 
conditions was comparable to the number observed with PRP. On the other hand, initially 
shear seemed to increase platelet attachment when tested with WP, but after 60 minutes 
this effect was not evident. Platelet-collagen interactions are mediated by a variety of 
receptors, both directly and through other plasma proteins such as vWF and Fg [137-
139]. Hence, even in the absence of plasma proteins platelet attachment levels were not 
greatly reduced.  
5.3.1.2 Platelet activation on 3D elastin and collagen scaffolds 
SEM images of purified collagen and elastin 3D scaffolds clearly showed the 
differences in surface topography between the two scaffolds, as seen in Figure 5.7. While 
the fibers on elastin scaffolds were thicker and clearly defined, the collagen scaffold 
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looked very irregular at the outset. At higher magnifications, thinner and more uneven 
fibers could be identified. 
    
    
Fig 5.7: SEM micrographs showing plain purified 3D collagen scaffolds (A & B) and 
elastin scaffolds (C & D). 
Similar to the results obtained with quantitative platelet attachment studies, SEM 
also revealed the superior platelet resistance of elastin scaffolds with PRP, both under 
static and shear conditions (Figure 5.8). In fact, under shear very few platelets could be 
spotted, and only at very high magnifications. Also, the attached platelets were rounded 
or dendritic with very limited pesudopodial extensions. 
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   Fig 5.8: SEM images of platelets attached to 3D elastin scaffolds with PRP under 
(A&B) static and (C&D)shear conditions. Solid arrows indicate rounded platelets and 
dashed arrows point to dendritic or spread dendritic morphologies. 
On the contrary, collagen scaffolds showed a noticeably higher occurance of 
attached and activated platelets. Due to irregularities with surface topography, the 
adhered platelets  could be discerned only at moderately higher magnifications. It can be 
seen from Figure 5.9 that there was no observable difference in the surface coverage of 
the activated platelets between samples tested under static and dynamic conditions. 
Overall, based on morphology most of the platelets were spread if not fully flattened. 
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Fig 5.9: SEM images of attached and activated platelets on 3D collagen scaffolds with 
PRP under (A) static and (B) shear. Dotted arrow marks denote spread/fully flattened 
platelets. 
When the scaffolds were incubated with the washed platelet suspension which 
does not contain plasma proteins, both elastin and collgen showed a higher degree of 
activated platelets on their surface.  
Elastin scaffolds showed both a higher surface coverage and a higher proportion 
of spread and fully flattened platelets under static conditions, whereas samples tested 
under shear showed fewer platelets which were morphologically rounded, dendritic or 
spread-dendritic (Figure 5.10). 
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Fig 5.10: SEM images showing platelet activation on 3D elastin scaffolds with WP under 
(A&B) static and (C&D)shear conditions. Plain arrows (       ) indicate rounded platelets, 
filled arrows (    ) show dendritic morphology and dotted arrows denote spread/flat 
platelets. 
Collagen scaffolds treated with washed platelets showed a higher number of 
platelets covering the surface under static conditions than under shear (Figure 5.11). 
However, morphologically the platelets under both states were spread with extended 
pseudopodia and some were also found to be completely flat. 
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Fig 5.11: SEM images of activated platelets on 3D collagen scaffolds with WP in the 
absence (A&B) and presence (C&D) of shear. Dotted arrow marks point to fully 
activated (spead and flat) platelets. 
5.3.1.3 Platelet attachment 2D elastin and collagen scaffolds 
We further tested platelet binding on 2D scaffolds (thin films) to find out if the 
data obtained in 3D scaffolds was due to different porosities of collagen and elastin 
scaffolds. Platelet attachment with PRP, on elastin and collagen-coated 2D converslips 
also showed similar results as 3D scaffolds, with a significant increase in the number of 
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platelets attached to collagen than elastin, both under static and shear conditions (Figure 
5.12).  
 
Fig 5.12: Platelet attachment with PRP on 2D elastin and collagen coated coverslips after 
(A) 15 minute and (B) 60 minute incubation. Elastin showed significantly lower platelet 
attachment than collagen (* and # represent p ≤ 0.05). 
Once again, this trend was not observed with washed platelet suspension, 
especially under shear (Figure 5.13). It is also important to note that in the presence of 
shear, the number of platelets attached to both the scaffolds was higher with washed 
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platelets than with PRP (Figure 5.12 and 5.13). Thus plasma proteins present in PRP are 
actually protecting both surfaces from platelet binding. 
 
Fig 5.13: Platelet attachment with WP on 2D elastin and collagen coated coverslips after 
(A) 15 minute and (B) 60 minute incubation showing increase in platelet attachment to 
elastin, in response to the absence of plasma proteins (* and # represent p ≤ 0.05).  
With both collagen and elastin-coated 2D surfaces, platelet attachment under 
shear was higher (barring collagen-WP-60 minutes) than what was observed under static 
conditions. This could be the effect of excessive deformation caused by subjecting the 
platelets to shear. 
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Interestingly when tested with washed platelets, it was observed that 
quantitatively the number of platelets attached on 2D collagen surfaces was higher than 
3D scaffolds (Figures 5.6 and 5.13) both under static and shear conditions. On the other 
hand, similar trend was seen only for those elastin samples that were maintained under 
shear.  This could potentially be due to easier accessibility of sites for platelet 
aggregation as topographical features like pores are absent in 2D scaffolds. Minelli et al 
have similarly observed that washed platelets preferably attach more to surfaces with 
minimal surface features and height [140].  
5.3.1.4 Platelet activation on 2D elastin and collagen scaffolds 
In the case of 2D scaffolds, elastin-coated coverslips showed almost no platelet 
attachment with PRP under static conditions unlike collagen, where a few platelet 
aggregates could be found as shown in Figure 5.14.  
   
Fig 5.14: SEM micrographs of 2D elastin (A) and collagen (B) coated coverslips treated 
with PRP under static conditions showing platelet aggregates only on collagen. 
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However, no SEM images could be obtained for both elastin and collagen 2D 
samples subjected to shear with PRP in spite of observing results with the platelet 
attachment assay (Figure 5.7). This could probably be due to the loosely adhered platelets 
getting dislodged during the several washing steps involved in SEM sample preparation 
and/or the general poor interaction of PRP with protein-coated glass coverslips as 
compared to TCPS surface over which proteins were coated for the platelet attachment 
assay. 
With WP, 2D scaffolds showed a significantly higher amount of platelet adhesion 
and activation. Elastin-coated surfaces showed a higher number of platelets, with most of 
them being dendritic or spread-dendritic under static conditions while under shear more 
clumps with spread and fully flattened platelets could be found (Figure 5.15). 
    
Fig 5.15: SEM images of platelet attachment and activation on elastin-coated coverslips 
with WP under (A) static condition showing dendritic and spread dentritic platelets, and 
(B) dynamic condition showing platelet spreading. 
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In contrast, collagen-coated coverslips were completely covered with fully 
flattened and a few spread platelets under static conditions (Figure 5.16). Samples 
incubated under shear showed a comparatively lower surface coverage with a few patches 
of the underlying collagen being seen. The morphology of the platelets was similar to that 
of scaffolds maintained under static conditions. 
    
 
Fig 5.16: SEM micrographs of activated and spread platelets found on 2D collagen 
surfaces with WP under (A&B) static and (C) shear. 
The following table (Table 5.2) summarizes the results observed with SEM, in 
terms of morphological grading of platelets adhered to both 3D and 2D collagen and 
elastin scaffolds. Platelets were assigned grades from 1 to 5 in the increasing order of 
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activation with rounded platelets denoted as 1, dendritic platelets as 2, spread dendritic 
platelets as 3, spread platelets as 4 and fully spread/flattened platelets as 5. 
 
Substrate and testing condition Morphological grading 
Elastin 3D 
PRP 
Static 1,2 
Shear 1 
WP 
Static 4,5 
Shear 3,4 
Collagen 3D 
PRP 
Static 4,5 
Shear 4 
WP 
Static 5 
Shear 5 
Elastin 2D 
PRP Static 0 
WP 
Static 2,3 
Shear 5 
 
Collagen 2D 
PRP Static 4 
WP 
Static 5 
Shear 4,5 
Table 5.2: Subjective gradation based on morphology of adhered platelets on 2D and 3D 
elastin and collagen scaffolds observed with SEM. 
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Taken together, it can be concluded from the platelet studies that in the presence 
of plasma proteins, which more closely resembles the conditions in vivo, elastin is much 
more resistant to platelet adhesion and activation both under static conditions and under 
shear.  
As expected, the 3D porous elastin scaffolds presenting a larger surface area 
showed higher number of platelets attached than elastin-coated 2D coverslips. Also, 
under shear fewer platelets were found on elastin scaffolds. When the plasma proteins 
were removed, the demarcation between collagen and elastin scaffolds was not clear, 
especially under shear when both elastin and collagen showed similar platelet adhesion. 
However, with respect to platelet activation, elastin scaffolds showed only isolated 
aggregates even with washed platelets under shear, unlike the highly thrombogenic 
collagen substrates. 
5.4 Plasma recalcification time 
Biomaterial contact is known to cause activation of Hageman factor (Factor XII) 
and set off the intrinsic pathway of coagulation. It involves a cascade of reactions in 
which calcium acts as a cofactor, ultimately resulting in the formation of a fibrin clot. 
Since this process is dependent on the material‟s surface properties, the dynamics of 
plasma clotting reflecting this activation can be used to assess the hemocompatibility of 
different biomaterials [141]. Glass which has a negatively charged, hydrophilic surface 
has shown to strongly support contact activation and hence was used to compare the 
values obtained for the test substrates. Recalcified plasma was added to the test samples 
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and the study was conducted for 20 minutes, which extends well beyond the time 
required for contact phase activation of normal plasma [142]. 
 
Fig 5.17 : Clotting time of recalcified plasma measured on glass, collagen and elastin 
substrates (* and # indicate p ≤ 0.05). 
Results obtained from the plasma recalcification analysis again proved that 
collagen possessed much higher procoagulant activity than elastin (Figure 5.17). With 
elastin, clotting time of approximately 567 ± 45 s was observed. Both collagen and glass 
showed significantly lesser times of about 246 ± 13 s and 240 ± 9 s respectively. Native 
collagen is documented to activate Hageman factor and the observed values agree with 
reported clotting times [114, 143]. We also checked the recalcification time on plain 
microcentrifuge tubes in which the reaction was carried out with the 3D scaffolds. None 
of the tubes (n = 5) showed coagulation within the test period of 1200 s. 
5.5 Circular dichroism 
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Fibrinogen plays an important role in blood-biomaterial interactions. It is one of 
the major constituents of the adsorbed protein layer on a biomaterial surface, owing to its 
high plasma concentration. Additionally, Fg adsorption and subsequent deformation 
largely influences platelet response to a foreign material [144]. From the platelet studies, 
it was evident that the presence of plasma proteins was essential to fully understand 
biomaterial hemocompatibility and neglecting this factor could greatly modify the 
platelet response. Hence we chose to study the adsorption of fibrinogen, one of the main 
players in this process, on elastin and collagen-coated substrates.  
 
Fig 5.18: Representative CD spectra of fibrinogen adsorbed on to elastin- and collagen-
coated quartz slides. 
Representative spectra of molar ellipticity Vs. wavelength (Figure 5.18) seemed 
to indicate differences in the negative peaks found at around 208 and 222 nm (important 
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in determining α-helical structures) for Fg adsorbed between collagen and elastin-coated 
surfaces.  
However, the percentage of secondary structural components, α-helix and β-sheet 
as evaluated by the SELCON software did not show any significant difference between 
the elastin- and collagen-coated quartz surfaces as compared to the corresponding values 
for native fibrinogen in solution (Figure 5.19) . 
 
Fig 5.19: Percentage composition of secondary structures of adsorbed Fg on protein-
coated substrates, compared to native Fg conformation. p ≤ 0.05 was considered 
statistically significant. 
This apparent similarity in behavior for collagen and elastin might in fact be due 
to the high concentration of protein used, which could potentially saturate the surface, 
thereby masking any differences of the actual surface-contacting protein layer. A higher 
degree of unfolding and denaturation was expected on the collagen-coated substrates, 
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since plasma protein unfolding is believed to present binding sites for other cellular 
components, ultimately contributing to the higher thrombogenicity of collagen as 
observed in platelet studies. However, the relative significance of direct collagen-
fibrinogen interactions is unclear as other plasma proteins such as vWF and fibronectin 
are primarily thought to interact with collagen [137, 145-147]. This could possibly 
explain the absence of any major changes in the observed values for the percentage 
composition of secondary structures of adsorbed Fg on collagen-coated quartz slides.  
One of the inherent limitations of working with protein-based substrates is the 
inability to follow rigorous cleaning procedures to ensure absolute purity of the substrate, 
as in the case of synthetic materials. Hence the possibility of interference due to surface-
bound impurities while taking background spectra measurements cannot be eliminated. 
Type of substrate Surface coverage of Fg adsorbed 
(µg/cm
2
) 
Elastin-coated quartz 0.8175 ± 0.059 
Collagen-coated quartz 0.4673 ± 0.030 
Table 5.3: Amount of fibrinogen adsorbed in µg/cm
2
 on elastin and collagen-coated 
quartz slides obtained from CD spectropolarimetry. 
Surface coverage was estimated based on the modified equation for calculating 
molar ellipticity from adsorbed protein concentration. Elastin-coated quartz surfaces 
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showed a marginally higher (albeit statistically significant) value for surface coverage 
than collagen-coated surfaces, as shown in Table 5.3. Interestingly, it can be noted from 
contact angle measurements that after incubation with water, elastin-coated coverslips 
were slightly more hydrophobic than collagen-coated substrates. For a given bulk protein 
concentration, the amount of adsorbed protein (represented here by surface coverage) 
increases with increasing hydrophobicity [148]. Also, surface coverage is inversely 
related to the extent of protein denaturation. The denser the surface packing of the 
adsorbed protein, the more they are restricted from structural rearrangement and 
denaturation [148]. Therefore, the lesser surface coverage of adsorbed Fg on collagen-
coated might in turn provide a greater opportunity for the protein to spread out. 
5.6 Endothelial cell retention 
Retention of seeded endothelial cells is critical for the performance of any 
cardiovascular biomaterial, especially to prevent unfavorable reactions with the host cells 
and plasma components immediately post-exposure. In this study, we investigated the 
ability of the purified 3D elastin scaffolds to support endothelial retention by itself, in the 
absence of serum proteins in vitro (since the amount of serum used for in vitro culture is 
extremely high when compared to physiological levels).   
It was observed that endothelial cell retention was comparable to TCPS at the end 
of the 10 minute incubation period, both under static and shear conditions. Under static 
conditions, the 3D elastin scaffolds showed good cellular retention, even after 30 
minutes, in the absence of serum proteins. However under shear, elastin was not capable 
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of retaining the majority of the cells when the incubation was extended to 30 minutes 
(Figure 5.20). 
 
Fig 5.20: Early time-point endothelial cell retention on elastin scaffolds under static and 
shear conditions after (A) 10 minutes and (B) 30 minutes of cell seeding (* represents p ≤ 
0.05). 
5.7 Adhesion inhibiton assay 
In order to improve the poor retention of endothelial cells on elastin scaffolds 
under shear, it is important to understand the process of adhesion and the contribution of 
specific receptors. This knowledge would help in improving cellular retention by 
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encouraging the activation of these receptors or stimulating their upregulation through 
appropriate molecular signals [149-152]. 
Integrins are the major class of adhesion molecules involved in cell-ECM 
interactions. They are heterodimeric receptors consisting of an α and a β subunit and 
require divalent cations for their function. As our test material elastin, was a purified 
ECM component, we chose to study the role of integrin receptors in mediating adhesion 
of the seeded endothelial cells to the scaffold.  
In the present study, three specific integrin subunits αv, α4 and β1 were assayed 
since their involvement has been implicated in endothelial adhesion to tropoelastin and 
other related subendothelial elastic fibre-associated molecules [153-157]. As we 
performed an adhesion inhibiton assay, the relative contribution of an individual receptor 
was deciphered by the extent of reduction in cellular retention upon its inhibition. 
Our results showed that both αv and β1 inhibition resulted in a distinct reduction 
in cellular retention of up to 25% with elastin, but α4 blocking did not have any effect 
after 30 minutes of incubation (Figure 5.21). By 45 minutes, the percentage retention had 
gone over 90% in all the groups, while there was no difference between the integrin-
inhibited and the no antibody control group at the end of 60 minutes incubation. 
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Fig 5.21: Adhesion inhibition assay on elastin, collagen and TCPS to understand 
involvement of integrin receptors in early adhesion of endothelial cells. All statistical 
analysis performed between sample group and no antibody control with p ≤ 0.05 being 
considered statistically signigicant (denoted by *,@ and #). 
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With the positive control, collagen, all the three integrin receptors appeared to 
contribute to adhesion. However, the decrease was not pronounced, approximately 6-7% 
(Figure 5.21). This could point to the role played by multiple integrin receptors in 
mediating endothelial adhesion to collagen substrates. Hence, blocking of one specific 
receptor did not significantly alter or decrease cellular retention. At the end of the 45 
minute incubation period, none of the blocking antibodies exercised any effect in 
inhibiting cell attachment. Predominantly α2β1, α1β1, α3β1 integrin receptors are said to 
be involved in interactions with collagen [158-161]. However, in our study no stark effect 
was observed by inhibiting the β1 subunit.  
On the other hand with TCPS which was the baseline control, αv and α4 blocking 
decreased cellular attachment by 7-8% after 30 minute incubation and this effect 
continued even after 45 minutes. But by 60 minutes, the antibodies failed to produce any 
statistically significant reduction in endothelial adhesion. In this case, β1 blocking was 
not successful probably since other β receptors could be involved in attachment to TCPS. 
The general trend of cell attachment observed with this adhesion inhibition assay 
with simultaneous introduction of cells and the blocking antibodies could be explained as 
follows (Figure 5.22). 
76 
 
 
Fig 5.22: Possible trend of cell attachment with the adhesion inhibition assay to study 
integrin-mediated early endothelial adhesion. 
Phase 1 represents the initial domination of cells attaching to the substrate, 
followed by Phase 2 wherein an equilibrium is reached between the cells trying to attach 
to the underlying substrate and the blocking antibodies which interfere with this 
adhesion. Phase 3 denotes the modulation of the cells to the new environment by 
compensating for the blocked receptors through facilitating attachment through different 
integrin receptors. Finally phase 4 or saturation is reached once the adhesion levels reach 
on par with the no antibody control. 
Based on this hypothesis, we could conclude that collagen was the most 
conducive substrate for endothelial attachment via various integrin receptors. Hence by 
30 minutes, it was likely to be in phase 3 and by 45 minutes the final phase of saturation 
had been attained. With elastin, at the end of 30 minutes, there was a pronounced effect 
of the blocking antibodies αv and β1, probably signifying phase 2. As time progressed, at 
45 minutes the percentage of cellular retention approached 100% possibly indicating the 
onset of phase 3 and by 60 minutes saturation was reached. On the other hand, with the 
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baseline control – TCPS, blocking antibodies against αv and α4 integrins had a minimal 
effect in inhibiting cell attachment. However, this effect was consistently seen after 30 
and 45 minutes incubation. Hence, it can be assumed that with TCPS, saturation (phase 
4) was reached over 45 minutes. Other integrin receptors potentially mediating adhesion 
to TCPS could be investigated to provide more insights into the dynamics of early 
endothelial attachment, as the receptors being studied did not seem to influence 
attachment significantly. 
Overall, with respect to early adhesion of endothelial cells to elastin scaffolds, 
integrin receptors αv and β1 seem to contribute considerably. It should also be noted that 
the adopted model of simultaneous interaction of the endothelial cells and inhibitory 
antibodies with the test substrate does not guarantee absolute elimination of the effect of 
the subunit being blocked, since some degree of initial attachment might occur even 
before the blocking antibodies bind to the endothelial cell surface integrin receptors. 
Taking this into consideration, the actual influence of the specific integrin subunits could 
be more pronounced than what was observed in the current study. 
 
 
 
 
 
78 
 
CHAPTER 6 – CONCLUSIONS AND RECOMMENDATIONS 
Hemocompatibility of purified elastin scaffolds was evaluated in vitro by studying 
platelet response to 2D and 3D scaffolds. Additionally, the influence of important factors 
such as presence of plasma proteins and shear was investigated. In general, elastin 
scaffolds showed a lower tendency to support platelet interactions when compared to 
equivalent protein-based scaffolds composed of collagen. Especially in a physiologically 
relevant milieu, in the presence of plasma proteins and shear, elastin exhibited superior 
platelet resistance and hemocompatibility as assessed quantitatively by LDH assay and 
morphologically by SEM. These results were further corroborated with plasma 
recalcification studies. Thus elastin-based tissue engineered scaffolds would be an 
attractive biomaterial for vascular graft applications. 
One of the interesting observations made from the present study was that plasma 
proteins drastically affect platelet response to a biomaterial. In order to further elucidate 
these effects, fibrinogen adsorption on elastin and collagen-coated substrates was studied. 
Though our results did not show any observable differences, possible explanations for 
this phenomenon could be provided by investigating the differences in plasma protein 
adsorption onto different materials. Future studies could be performed with other critical 
proteins such as vWF, globulins and also at lower concentrations of plasma proteins to 
prevent substrate saturation.  
Maintaining a patent endothelial lining is known to improve vascular graft 
performance. However in the current study it was seen that retention of seeded 
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endothelial cells on these elastin scaffolds was poor under shear when endothelial cells 
were not allowed to attach prior to applying shear stress. Thus, static endothelial seeding 
should be pursued in vitro so that endothelial cells will have time to attach and proliferate 
prior to putting them in fluid flow. We also investigated integrin-mediated adhesion of 
endothelial cells to elastin and collagen scaffolds. Among the subunits studied, both αv 
and β1 contributed significantly to endothelial adhesion on purified elastin substrates. 
Further studies on encouraging receptor-specific adhesion through pre-stimulation could 
be carried out for successful endothelialization of elastin scaffolds in vitro prior to 
implantation. Apart from enabling adhesion, ability of these scaffolds in supporting 
endothelial cell proliferation has to be evaluated, since cellular proliferation is essential to 
maintain a confluent monolayer at the luminal surface.  
Finally, in order to successfully translate the use of purified elastin scaffolds into 
clinical applications, in vivo hemocompatibility and functional efficacy has to be assessed 
with appropriate animal models. Also, long-term evaluation of the tissue engineered 
scaffold in facilitating host tissue remodeling and regeneration has to be performed, 
which is the ultimate goal of a living vascular substitute. 
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